Japan, which boasts the world's highest longevity rate, is experiencing major increases in medical costs that are causing the National Health Insurance system to buckle under the burden.

Chemiphar sees its role in society as a provider of original and generic pharmaceuticals to help people become and remain healthy. This goal is echoed by the Company's two main business areas.

1. Generics business
Chemiphar is seeking to boost its presence in the generic-drug market by focusing on pharmacies, clinics and, in particular, the hospital sector. To this end, the Company is providing safe and efficacious generics and adequate product information that includes proper product use, drug efficacy, and safety information about any side effects.

2. Branded pharmaceuticals business
Chemiphar is providing patients with effective, safe ethical pharmaceuticals through hospitals and pharmacies.

As part of its ongoing bid to strengthen the position of Uralyt in the hyperuricemia* market, Chemiphar is doing its best to increase social awareness concerning the importance of the early treatment of hyperuricemia, which has been recognized as a life-style disease.

We believe that one of our social responsibilities is to help reduce the medical costs borne by patients and the government.

Kazushiro Yamaguchi
President&CEO

• * Hyperuricemia is a clinical condition in which the uric acid level in 1 deciliter of blood serum is over 7.0 milligrams. Without treatment, it may lead to gout, which causes severe pain, usually in the toe. In addition, hyperuricemia may lead to kidney impairment and urinary calculus, as well as hardened arteries, a condition related to cardiac infarction and stroke.